Luigi Muratori

Prof. Luigi Muratori


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2023 in BMJ
Verified
Journal Article
Open access
PDF file
LMLuigi Muratori
Luigi Muratori
ALAnsgar W Lohse
Ansgar W Lohse
MLMarco Lenzi
Marco Lenzi
Autoimmune hepatitis is an inflammatory disease of the liver of unknown cause that may progress to liver cirrhosis and end stage liver failure if diagnosis is overlooked and treatment delayed. The clinical presentation is often that of acute hepatitis, sometimes very severe; less frequently, it can be insidious or completely asymptomatic. The disease can affect people of any age and is more common in women; its incidence and prevalence seem to be on the rise worldwide. An abnormal immune response targeting liver autoantigens and inducing persistent and self-perpetuating liver inflammation is the pathogenic mechanism of the disease. A specific set of autoantibodies, increased IgG concentrations, and histological demonstration of interface hepatitis and periportal necrosis are the diagnostic hallmarks of autoimmune hepatitis. Prompt response to treatment with corticosteroids and other immunomodulatory drugs is almost universal and supports the diagnosis. The aims of treatment are to induce and maintain long term remission of liver inflammation. Treatment can often even reverse liver fibrosis, thus preventing progression to advanced cirrhosis and its complications. Most patients need lifelong maintenance therapy, and repeated follow-up in experienced hands improves the quality of care and quality of life for affected patients.

1 May 2008 in Clinics in Liver Disease
Verified
Journal Article
Closed access
LMLuigi Muratori
Luigi Muratori
Alessandro GranitoAlessandro Granito
Alessandro Granito
PMPaolo Muratori
Paolo Muratori
GPGeorgios Pappas
Georgios Pappas
FBFrancesco B. Bianchi
Francesco B. Bianchi

23 April 2014 in Liver International
Verified
Journal Article
Closed access
PDF file
CQChiara Quarneti
Chiara Quarneti
PMPaolo Muratori
Paolo Muratori
CLClaudine Lalanne
Claudine Lalanne
AFAngela Fabbri
Angela Fabbri
RMRita Menichella
Rita Menichella
LMLuigi Muratori
Luigi Muratori

1 June 2005 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
LMLuigi Muratori
Luigi Muratori
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
PMPaolo Muratori
Paolo Muratori
MLMarco Lenzi
Marco Lenzi
Alessandro GranitoAlessandro Granito
Alessandro Granito
DVDiego Vergani
Diego Vergani

1 November 2018 in Journal of Autoimmunity
Verified
Journal Article
Open access
BBBenedetta Terziroli Beretta-Piccoli
Benedetta Terziroli Beretta-Piccoli
PRPaolo Ripellino
Paolo Ripellino
CGClaudio Gobbi
Claudio Gobbi
ACAndreas Cerny
Andreas Cerny
ABAdriana Baserga
Adriana Baserga
LMLuigi Muratori
Luigi Muratori
The etiology of autoimmune hepatitis (AIH) is unknown, though hepatotropic viruses may be potential triggers. Hepatitis E virus (HEV) infection, an increasingly recognized cause of acute hepatitis, has been misdiagnosed as AIH due to the occurrence of autoantibodies during its acute phase. It has also been suggested that HEV infection may lead to or unmask AIH. The HEV seroprevalence has been ascertained in patients with AIH, but the prevalence of AIH-related autoantibodies in patients with HEV infection has not been systematically tested. We aimed to investigate whether acute HEV infection is associated with the presence of AIH-relevant autoantibodies, following the liver autoimmune serology guidelines of the International AIH Group. We tested 48 patients with acute HEV infection. Half of them had at least one autoantibody, 17% two autoantibodies. Anti-nuclear antibody (ANA) were detected in 16 (33%), anti-smooth muscle antibody (SMA) in 10 (21%), and anti-neutrophil cytoplasmic antibody (ANCA) in 7 (14.6%). Of note, two patients showed SMA with VG or VGT patterns and five had ANA with homogeneous appearance, both being typical of AIH type 1. Other AIH-specific autoantibodies were negative. Atypical anti-mitochondrial antibody, without evidence of primary biliary cholangitis, was positive in one patient, disappearing at follow-up. Follow-up (median 12 months) serum was available from seven autoantibody positive patients: two became negative, while five remained positive, although no patient developed AIH to date. In conclusion, autoantibodies are frequently present during acute HEV infection, indicating that HEV should always be excluded before diagnosing AIH. Importantly, a minority of patients with acute hepatitis E develops AIH-specific autoantibodies, and, though they did not progress to autoimmune liver disease in the short-term, they warrant long-term monitoring.

15 November 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMPaolo Murator
Paolo Murator
LMLuigi Muratori
Luigi Muratori
GVGabriella Verucchi
Gabriella Verucchi
LALuciano Attard
Luciano Attard
FBFrancesco B. Bianchi
Francesco B. Bianchi
MLMarco Lenzi
Marco Lenzi
We evaluated the prevalence and clinical significance of non—organ-specific autoantibodies (NOSAs) in 47 hepatitis C virus (HCV)–positive children wi